Cognivia Shareholder Update

From Perplex City Wiki
Revision as of 16:57, 21 April 2006 by Scott (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search

cnvc o g n i v i a

Shareholder Update

March 269

cnvc o g n i v i a Shareholder Update

March 269

a brighter future

Cognivia is leaner, fitter and better placed than ever. Over the past financial

year, our share of the cognitive enhancement retail market increased from 68%

to 69%, leading to an increase in turnover of 3.2%.

Coupled with our internal efficiency programme and streamlined distribution

network, this gave us a 4.7% rise in profits (before exceptional items).

Progress in mind

Our investments in AI continue to produce extremely promising results. Agilon

is on the verge of completing its new City Behavioural Model, which will prove

invaluable to anyone wishing to predict citizensʼ reactions to a huge variety of

stimuli – from natural disasters to marketing campaigns.

Completing the picture

In prosthetics, weʼre forging ahead in our development of nanotechnology.

Within the year, we expect to have completed the core work on our neural scanner,

which will allow us to map and replicate the networks of any part of the

brain. It will soon be possible to scan a healthy brain in its entirety and, if it is

damaged in later life, to recreate a prosthesis of the damaged region.

The winning formula

This year, we also continued our successful association with the PCAG. The

exposure this gives Cognivia is a key factor in our domination of the market,

and weʼve been working hard to maintain our position as the PCAGʼs partner of

choice.

To keep up with the latest enhancement and concealment techniques, our biodata

scans have been upgraded to include a full genetic profile, highlighting any

signs of gene therapy. And as cerebral prosthetics become more and more

sophisticated, weʼve developed new methods for detecting and disabling nanotechnology.


cnvc o g n i v i a Shareholder Update

March 269

evolution, accelerated

For millions of years, life has been a missed opportunity. Generations of human

beings have been able to access only a fraction of their mental capacity, never

reaching their full potential.

In the past twenty years, Cognivia has taken the human mind to new levels. The

ability to enhance our own faculties has heralded the start of a new evolutionary

era. Mankind has entered the Mind Age.

The next generation

And now, weʼre preparing to take the next step in that evolution. Ceretin 6 is in

its final test phase, having already shown significantly improved performance

over the current generation of Ceretin.

Very soon, Cognivia customers will have the opportunity to be even faster,

sharper and more alert. Imagine the difference it could make to your life.

Natural selection

Before we move forward in our development, we want to be absolutely sure that

weʼre heading in the right direction. Thatʼs why weʼre taking a little more time

to perfect Ceretin 6, making certain that we understand any test anomalies.

The testing phase is designed to highlight issues as early as possible. It is doing

exactly that. Rather than worry about the extended test process, we should be

glad that any imperfections have been detected at a stage when we can study

and correct them.

The human race has waited millions of years to reach this point. We can afford

to spend a few more months sharpening our future.


cnvc o g n i v i a Shareholder Update

March 269

thinking ahead

This has been a great year for Cognivia, in the face of challenging conditions.

Not only have we produced our best ever financial results, but weʼve also laid

the foundations for future success.

All our shareholders can feel confident that their investment will continue to

grow, as we work to improve the lives of our citizens in a financially responsible

manner.

Proof copies of the forthcoming C6 research paper will be available to CE professionals

in April 269.

For further details, please contact us at media@cognivia.com or log into

your secure account.